The company will imminently start its third pivotal trial of PF-08634404.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
Seagen/Genmab’s confirmatory cervical cancer trial is toplined positive, putting up a fresh roadblock for Iovance’s accelerated filing plans.
Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.
The company’s radiopharmaceutical PNT2002 faces a major fourth-quarter catalyst, and US filing could follow.
Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.
A royalty financing deal should see this gene therapy launched nine months after its surprise US approval.
Phase 1 data for divarasib in lung and colorectal cancers look good versus Lumakras and Krazati’s earlier showings.